Between 1962 and 1985, cancer-related deaths in the United States rose by 8.7%, despite the use of aggressive chemotherapy drugs and radiation therapy, highlighting the dangers of a one-size-fits-all approach to treatment. An understanding of the genetic determinants of patients’ therapeutic response, it was believed, would enable doctors to develop individualized treatment programs, sparing more responsive patients from harmful overtreatment.